DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
STIM logo

Neuronetics, Inc. Stock Price

NasdaqGM:STIM Community·US$229.4m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

STIM Share Price Performance

US$3.03
-0.10 (-3.04%)
​
US$6.00
Fair Value
US$3.03
-0.10 (-3.04%)
49.5% undervalued intrinsic discount
US$6.00
Fair Value
Price US$3.03
AnalystConsensusTarget US$6.00
AnalystHighTarget US$7.00
AnalystLowTarget US$5.00
Thu, 27 Aug 26
Fair ValueUS$6.00
Share Pricen/a

STIM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$6 49.5% undervalued intrinsic discount

Expanding Mental Healthcare Outreach Will Unlock Future Potential

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$7 56.7% undervalued intrinsic discount

Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$5 39.4% undervalued intrinsic discount

Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
STIM logo
Neuronetics
49.5% undervalued intrinsic discount

Expanding Mental Healthcare Outreach Will Unlock Future Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 27 Aug
Read Narrative
STIM logo
Neuronetics
39.4% undervalued intrinsic discount
Updated

Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 10 Sep
Read Narrative
STIM logo
Neuronetics
56.7% undervalued intrinsic discount

Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 18 Mar
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
STIM logo

STIM: Vertically Integrated Mental Health Platform Will Drive Long-Term Upside Potential

Fair Value: US$5 39.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
STIM logo

STIM: Vertically Integrated Interventional Psychiatry Platform Will Support Future Repricing Potential

Fair Value: US$6 49.5% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
STIM logo

Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade

Fair Value: US$7 56.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Fair value with mediocre balance sheet.

3 Risks
1 Reward
View Full Analysis

Neuronetics, Inc. Key Details

US$155.1m

Revenue

US$78.5m

Cost of Revenue

US$76.6m

Gross Profit

US$107.0m

Other Expenses

-US$30.4m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.40
49.38%
-19.62%
284.3%
View Full Analysis

About STIM

Founded
2001
Employees
658
CEO
Daniel Reuvers
WebsiteView website
neurostar.com/neuronetics

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Recent STIM News & Updates

User avatar
Narrative Update • Sep 10

STIM: Vertically Integrated Mental Health Platform Will Drive Long-Term Upside Potential

Analysts have lifted their fair value estimate for Neuronetics from $3 to $5. They point to the Greenbrook TMS acquisition and the shift toward a vertically integrated mental health platform with 93 company-operated treatment centers as key reasons for the higher price target and what they view as a compelling risk and reward profile.
User avatar
Narrative Update • Aug 27

STIM: Vertically Integrated Interventional Psychiatry Platform Will Support Future Repricing Potential

Analysts have adjusted their fair value estimate for Neuronetics to $6.00 from $5.25, reflecting updated views on the company following its Greenbrook TMS acquisition and the potential they see in its expanded mental health treatment platform. What’s in the News for Neuronetics Neuronetics narrowed its full year 2026 total revenue guidance to a range of US$160 million to US$164 million, compared with the prior range of US$160 million to US$166 million.

Recent updates

No updates

Neuronetics, Inc. Competitors

SSII logo

SS Innovations International

Symbol: NasdaqCM:SSII
Market cap: US$661.3m
SOPH logo

SOPHiA GENETICS

Symbol: NasdaqGS:SOPH
Market cap: US$647.8m
PHR logo

Phreesia

Symbol: NYSE:PHR
Market cap: US$631.3m
ANGO logo

AngioDynamics

Symbol: NasdaqGS:ANGO
Market cap: US$629.9m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide